EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)VergleichsstudieOpen Access · CC BY-NC 3.0

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants

Weimin Li iD, Sami Z Daoud, Roopa Trivedi, Pradeep B Lukka, Eulalia Jimenez, Eduard Molins, Catherine Stewart, Pranob Bharali, Esther Garcia-Gil

International Journal of Chronic Obstructive Pulmonary Disease · 2023

DOI: 10.2147/copd.s434588 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2023. Verfasst von Weimin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, People's Republic of China. Hauptthemen laut MEDLINE: Muscarinic Antagonists, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscarinic AntagonistsPulmonary Disease, Chronic ObstructiveHumansArea Under CurveDose-Response Relationship, DrugEast Asian PeopleHealthy VolunteersTropanesWhite PeopleAdministration, InhalationAdolescentYoung AdultAdultMiddle Aged

Stichwörter der Autor:innen

Chinaaclidinium bromidebronchodilatorchronic obstructive pulmonary diseasepharmacokineticssafety

Substanzen

aclidinium bromideMuscarinic AntagonistsTropanes

Autor:innen und Institutionen

  • Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
  • Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
  • Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain.
  • Statistics, Phastar, Chiswick, London, UK.

ORCID-Profile: Weimin Li

Zitieren

APA

Li, W., Daoud, S. Z., Trivedi, R., Lukka, P. B., Jimenez, E., Molins, E., Stewart, C., Bharali, P., & Garcia-Gil, E. (2023). The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s434588

Vancouver

Li W, Daoud SZ, Trivedi R, Lukka PB, Jimenez E, Molins E, et al. The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants. International Journal of Chronic Obstructive Pulmonary Disease. 2023. doi:10.2147/copd.s434588

BibTeX
@article{Li2023,
  author = {Li, Weimin and Daoud, Sami Z and Trivedi, Roopa and Lukka, Pradeep B and Jimenez, Eulalia and Molins, Eduard and Stewart, Catherine and Bharali, Pranob and Garcia-Gil, Esther},
  title = {The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2023},
  doi = {10.2147/copd.s434588}
}
Kostenlos starten →